Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 155

1.

Synthesis of new acylsulfamoyl benzoxaboroles as potent inhibitors of HCV NS3 protease.

Li X, Zhang YK, Liu Y, Zhang S, Ding CZ, Zhou Y, Plattner JJ, Baker SJ, Liu L, Bu W, Kazmierski WM, Wright LL, Smith GK, Jarvest RL, Duan M, Ji JJ, Cooper JP, Tallant MD, Crosby RM, Creech K, Ni ZJ, Zou W, Wright J.

Bioorg Med Chem Lett. 2010 Dec 15;20(24):7493-7. doi: 10.1016/j.bmcl.2010.10.007. Epub 2010 Oct 30.

PMID:
21041080
2.

Synthesis and biological evaluations of P4-benzoxaborole-substituted macrocyclic inhibitors of HCV NS3 protease.

Ding CZ, Zhang YK, Li X, Liu Y, Zhang S, Zhou Y, Plattner JJ, Baker SJ, Liu L, Duan M, Jarvest RL, Ji J, Kazmierski WM, Tallant MD, Wright LL, Smith GK, Crosby RM, Wang AA, Ni ZJ, Zou W, Wright J.

Bioorg Med Chem Lett. 2010 Dec 15;20(24):7317-22. doi: 10.1016/j.bmcl.2010.10.071. Epub 2010 Oct 21.

PMID:
21067923
3.

Novel macrocyclic HCV NS3 protease inhibitors derived from α-amino cyclic boronates.

Li X, Zhang YK, Liu Y, Ding CZ, Zhou Y, Li Q, Plattner JJ, Baker SJ, Zhang S, Kazmierski WM, Wright LL, Smith GK, Grimes RM, Crosby RM, Creech KL, Carballo LH, Slater MJ, Jarvest RL, Thommes P, Hubbard JA, Convery MA, Nassau PM, McDowell W, Skarzynski TJ, Qian X, Fan D, Liao L, Ni ZJ, Pennicott LE, Zou W, Wright J.

Bioorg Med Chem Lett. 2010 Oct 1;20(19):5695-700. doi: 10.1016/j.bmcl.2010.08.022. Epub 2010 Aug 10.

PMID:
20801653
4.

Inhibitors of hepatitis C virus NS3/4A: alpha-ketoamide based macrocyclic inhibitors.

Avolio S, Robertson K, Hernando JI, DiMuzio J, Summa V.

Bioorg Med Chem Lett. 2009 Apr 15;19(8):2295-8. doi: 10.1016/j.bmcl.2009.02.079. Epub 2009 Feb 25.

PMID:
19285390
5.

Novel P2-P4 macrocyclic inhibitors of HCV NS3/4A protease by P3 succinamide fragment depeptidization strategy.

Pompei M, Di Francesco ME, Pesci S, Koch U, Vignetti SE, Veneziano M, Pace P, Summa V.

Bioorg Med Chem Lett. 2010 Jan 1;20(1):168-74. doi: 10.1016/j.bmcl.2009.11.005. Epub 2009 Nov 10.

PMID:
19932966
6.

Synthesis and SAR of acyclic HCV NS3 protease inhibitors with novel P4-benzoxaborole moieties.

Li X, Zhang S, Zhang YK, Liu Y, Ding CZ, Zhou Y, Plattner JJ, Baker SJ, Bu W, Liu L, Kazmierski WM, Duan M, Grimes RM, Wright LL, Smith GK, Jarvest RL, Ji JJ, Cooper JP, Tallant MD, Crosby RM, Creech K, Ni ZJ, Zou W, Wright J.

Bioorg Med Chem Lett. 2011 Apr 1;21(7):2048-54. doi: 10.1016/j.bmcl.2011.02.006. Epub 2011 Feb 23.

PMID:
21353550
7.

Pyrrolidine-5,5-trans-lactams. 4. Incorporation of a P3/P4 urea leads to potent intracellular inhibitors of hepatitis C virus NS3/4A protease.

Slater MJ, Amphlett EM, Andrews DM, Bamborough P, Carey SJ, Johnson MR, Jones PS, Mills G, Parry NR, Somers DO, Stewart AJ, Skarzynski T.

Org Lett. 2003 Nov 27;5(24):4627-30.

PMID:
14627400
8.

Novel potent macrocyclic inhibitors of the hepatitis C virus NS3 protease: use of cyclopentane and cyclopentene P2-motifs.

Bäck M, Johansson PO, Wångsell F, Thorstensson F, Kvarnström I, Ayesa S, Wähling H, Pelcman M, Jansson K, Lindström S, Wallberg H, Classon B, Rydergård C, Vrang L, Hamelink E, Hallberg A, Rosenquist S, Samuelsson B.

Bioorg Med Chem. 2007 Nov 15;15(22):7184-202. Epub 2007 Aug 22.

PMID:
17845856
9.

Novel macrocyclic inhibitors of hepatitis C NS3/4A protease featuring a 2-amino-1,3-thiazole as a P4 carbamate replacement.

Di Francesco ME, Dessole G, Nizi E, Pace P, Koch U, Fiore F, Pesci S, Di Muzio J, Monteagudo E, Rowley M, Summa V.

J Med Chem. 2009 Nov 26;52(22):7014-28. doi: 10.1021/jm900524b.

PMID:
19856919
10.

Synthesis and antiviral activity of HCV NS3/4A peptidomimetic boronic acid inhibitors.

Boloor A, Hanway D, Joshi M, Winn DT, Mendez G, Walls M, Wei P, Qian F, Zhang X, Zhang Y, Hepperle ME, Li X, Campbell DA, Betancort JM.

Bioorg Med Chem Lett. 2009 Oct 1;19(19):5708-11. doi: 10.1016/j.bmcl.2009.08.017. Epub 2009 Aug 8.

PMID:
19713109
11.

Development of macrocyclic inhibitors of HCV NS3/4A protease with cyclic constrained P2-P4 linkers.

Rudd MT, McIntyre CJ, Romano JJ, Butcher JW, Holloway MK, Bush K, Nguyen KT, Gilbert KF, Lyle TA, Liverton NJ, Wan BL, Summa V, Harper S, Rowley M, Vacca JP, Carroll SS, Burlein C, DiMuzio JM, Gates A, Graham DJ, Huang Q, Ludmerer SW, McClain S, McHale C, Stahlhut M, Fandozzi C, Taylor A, Trainor N, Olsen DB, McCauley JA.

Bioorg Med Chem Lett. 2012 Dec 1;22(23):7207-13. doi: 10.1016/j.bmcl.2012.09.061. Epub 2012 Oct 2.

PMID:
23084906
12.

Inhibitors of hepatitis C virus NS3.4A protease. Effect of P4 capping groups on inhibitory potency and pharmacokinetics.

Perni RB, Chandorkar G, Cottrell KM, Gates CA, Lin C, Lin K, Luong YP, Maxwell JP, Murcko MA, Pitlik J, Rao G, Schairer WC, Van Drie J, Wei Y.

Bioorg Med Chem Lett. 2007 Jun 15;17(12):3406-11. Epub 2007 Apr 3.

PMID:
17482818
13.

Advances in the development of macrocyclic inhibitors of hepatitis C virus NS3-4A protease.

Avolio S, Summa V.

Curr Top Med Chem. 2010;10(14):1403-22. Review.

PMID:
20536420
14.

Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease.

Liverton NJ, Holloway MK, McCauley JA, Rudd MT, Butcher JW, Carroll SS, DiMuzio J, Fandozzi C, Gilbert KF, Mao SS, McIntyre CJ, Nguyen KT, Romano JJ, Stahlhut M, Wan BL, Olsen DB, Vacca JP.

J Am Chem Soc. 2008 Apr 9;130(14):4607-9. doi: 10.1021/ja711120r. Epub 2008 Mar 14.

PMID:
18338894
15.

Development of potent macrocyclic inhibitors of genotype 3a HCV NS3/4A protease.

Rudd MT, McCauley JA, Romano JJ, Butcher JW, Bush K, McIntyre CJ, Nguyen KT, Gilbert KF, Lyle TA, Holloway MK, Wan BL, Vacca JP, Summa V, Harper S, Rowley M, Carroll SS, Burlein C, DiMuzio JM, Gates A, Graham DJ, Huang Q, Ludmerer SW, McClain S, McHale C, Stahlhut M, Fandozzi C, Taylor A, Trainor N, Olsen DB, Liverton NJ.

Bioorg Med Chem Lett. 2012 Dec 1;22(23):7201-6. doi: 10.1016/j.bmcl.2012.08.106. Epub 2012 Sep 7.

PMID:
23021993
16.

Synthesis and SAR of potent inhibitors of the Hepatitis C virus NS3/4A protease: exploration of P2 quinazoline substituents.

Nilsson M, Belfrage AK, Lindström S, Wähling H, Lindquist C, Ayesa S, Kahnberg P, Pelcman M, Benkestock K, Agback T, Vrang L, Terelius Y, Wikström K, Hamelink E, Rydergård C, Edlund M, Eneroth A, Raboisson P, Lin TI, de Kock H, Wigerinck P, Simmen K, Samuelsson B, Rosenquist S.

Bioorg Med Chem Lett. 2010 Jul 15;20(14):4004-11. doi: 10.1016/j.bmcl.2010.05.029. Epub 2010 May 21.

PMID:
20541405
17.

Synthesis and optimization of a novel series of HCV NS3 protease inhibitors: 4-arylproline analogs.

Bilodeau F, Bailey MD, Bhardwaj PK, Bordeleau J, Forgione P, Garneau M, Ghiro E, Gorys V, Halmos T, Jolicoeur ES, Leblanc M, Lemke CT, Naud J, O'Meara J, White PW, Llinàs-Brunet M.

Bioorg Med Chem Lett. 2013 Jul 15;23(14):4267-71. doi: 10.1016/j.bmcl.2013.03.043. Epub 2013 Mar 19.

PMID:
23735741
18.

Pyrrolidine-5,5-trans-lactams. 1. Synthesis and incorporation into inhibitors of hepatitis C virus NS3/4A protease.

Andrews DM, Carey SJ, Chaignot H, Coomber BA, Gray NM, Hind SL, Jones PS, Mills G, Robinson JE, Slater MJ.

Org Lett. 2002 Dec 12;4(25):4475-8.

PMID:
12465916
19.

Potent triazolyl-proline-based inhibitors of HCV NS3 protease.

Naud J, Lemke C, Goudreau N, Beaulieu E, White PD, Llinàs-Brunet M, Forgione P.

Bioorg Med Chem Lett. 2008 Jun 1;18(11):3400-4. doi: 10.1016/j.bmcl.2008.04.012. Epub 2008 Apr 10.

PMID:
18448339
20.

Discovery of novel P3-oxo inhibitor of hepatitis C virus NS3/4A serine protease.

Duan M, Kazmierski W, Crosby R, Gartland M, Ji J, Tallant M, Wang A, Hamatake R, Wright L, Wu M, Zhang YK, Ding CZ, Li X, Liu Y, Zhang S, Zhou Y, Plattner JJ, Baker SJ.

Bioorg Med Chem Lett. 2012 Apr 15;22(8):2993-6. doi: 10.1016/j.bmcl.2012.02.039. Epub 2012 Feb 22.

PMID:
22425454
Items per page

Supplemental Content

Write to the Help Desk